Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?

被引：23
作者：
Higano, Celestia [1 ,2 ]
机构：
[1] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
来源：
NATURE REVIEWS UROLOGY | 2019年 / 16卷 / 06期
关键词：
RESISTANT PROSTATE-CANCER; METASTASIS-FREE SURVIVAL; MEN;
D O I：
10.1038/s41585-019-0186-2
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The PROSPER, SPARTAN, and ARAMIS trials demonstrated the efficacy of enzalutamide, apalutamide, and darolutamide, respectively, to extend metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. However, questions remain regarding patient selection for these agents, particularly concerning adverse effects, patient PSA doubling time, and cost and formulary considerations.
引用
收藏
页码：335 / 336
页数：3
相关论文
共 9 条
  • [1] Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
    Fizazi, Karim
    Shore, Neal
    Tammela, Teuvo L.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (13) : 1235 - 1246
  • [2] Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
    Hussain, Maha
    Fizazi, Karim
    Saad, Fred
    Rathenborg, Per
    Shore, Neal
    Ferreira, Ubirajara
    Ivashchenko, Petro
    Demirhan, Eren
    Modelska, Katharina
    Phung, De
    Krivoshik, Andrew
    Sternberg, Cora N.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26) : 2465 - 2474
  • [3] Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
    Moilanen, Anu-Maarit
    Riikonen, Reetta
    Oksala, Riikka
    Ravanti, Laura
    Aho, Eija
    Wohlfahrt, Gerd
    Nykanen, Pirjo S.
    Tormakangas, Olli P.
    Palvimo, Jorma J.
    Kallio, Pekka J.
    [J]. SCIENTIFIC REPORTS, 2015, 5
  • [4] Ruiz Garcia P, 2016, ANN ONCOL S, V27, p738P
  • [5] Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
    Scher, Howard I.
    Beer, Tomasz M.
    Higano, Celestia S.
    Anand, Aseem
    Taplin, Mary-Ellen
    Efstathiou, Eleni
    Rathkopf, Dana
    Shelkey, Julia
    Yu, Evan Y.
    Alumkal, Joshi
    Hung, David
    Hirmand, Mohammad
    Seely, Lynn
    Morris, Michael J.
    Danila, Daniel C.
    Humm, John
    Larson, Steve
    Fleisher, Martin
    Sawyers, Charles L.
    [J]. LANCET, 2010, 375 (9724) : 1437 - 1446
  • [6] Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure The UPWARD Study
    Slovin, Susan
    Clark, William
    Carles, Joan
    Krivoshik, Andrew
    Park, Jung Wook
    Wang, Fong
    George, Daniel
    [J]. JAMA ONCOLOGY, 2018, 4 (05) : 702 - 706
  • [7] Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
    Smith, Matthew R.
    Saad, Fred
    Chowdhury, Simon
    Oudard, Stephane
    Hadaschik, Boris A.
    Graff, Julie N.
    Olmos, David
    Mainwaring, Paul N.
    Lee, Ji Youl
    Uemura, Hiroji
    Lopez-Gitlitz, Angela
    Trudel, Geralyn C.
    Espina, Byron M.
    Shu, Youyi
    Park, Youn C.
    Rackoff, Wayne R.
    Yu, Margaret K.
    Small, Eric J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (15) : 1408 - 1418
  • [8] Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time
    Smith, Matthew R.
    Saad, Fred
    Oudard, Stephane
    Shore, Neal
    Fizazi, Karim
    Sieber, Paul
    Tombal, Bertrand
    Damiao, Ronaldo
    Marx, Gavin
    Miller, Kurt
    Van Veldhuizen, Peter
    Morote, Juan
    Ye, Zhishen
    Dansey, Roger
    Goessl, Carsten
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (30) : 3800 - +
  • [9] Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials.
    Tombal, Bertrand F.
    Armstrong, Andrew J.
    Barrus, Jeffrey Kent
    Beer, Tomasz M.
    Chowdhury, Simon
    Evans, Christopher P.
    Heidenreich, Axel
    Higano, Celestia S.
    Kamba, Tomomi
    Lin, Ping
    Nikolayeva, Natalia
    Sugg, Jennifer
    Steinberg, Joyce Leta
    Taplin, Mary Ellen
    Saad, Fred
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
1